StockData
Coherus Oncology, Inc. logo

Coherus Oncology, Inc. (CHRS) stock

CHRSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/3065% below fair value
$0.41−0.07 (-14.34%)

Close on Nov 18, 2026Market cap $63.33MP/E –Yield –

Coherus Oncology pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Coherus Oncology's pe ratio was 1.2× on Jul 31, 2026, against 0.5× a year earlier. Over the last 3 years it ranged from 0.3× to 15.7×, with a median of 4.1×.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Jul 31, 20261.2×+0.8
2025Dec 31, 20250.3×−8.8
2021Apr 30, 20219.1×+0.6
2020Dec 31, 20208.5×–

More Coherus Oncology figures

See a number that looks wrong?